These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 35512517)
1. Evaluation of Bailey TA; Wacker JN; An DD; Carter KP; Davis RC; Mocko V; Larrabee J; Shield KM; Lam MN; Booth CH; Abergel RJ Nucl Med Biol; 2022; 110-111():28-36. PubMed ID: 35512517 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of Bobba KN; Bidkar AP; Meher N; Fong C; Wadhwa A; Dhrona S; Sorlin A; Bidlingmaier S; Shuere B; He J; Wilson DM; Liu B; Seo Y; VanBrocklin HF; Flavell RR J Nucl Med; 2023 Jul; 64(7):1076-1082. PubMed ID: 37201957 [No Abstract] [Full Text] [Related]
3. A comparison of DFO and DFO* conjugated to trastuzumab-DM1 for complexing Cho H; Al-Saden N; Lam H; Möbus J; Reilly RM; Winnik MA Nucl Med Biol; 2020; 84-85():11-19. PubMed ID: 31931305 [TBL] [Abstract][Full Text] [Related]
4. Development of CD46 targeted alpha theranostics in prostate cancer using Bobba KN; Bidkar AP; Wadhwa A; Meher N; Drona S; Sorlin AM; Bidlingmaier S; Zhang L; Wilson DM; Chan E; Greenland NY; Aggarwal R; VanBrocklin HF; He J; Chou J; Seo Y; Liu B; Flavell RR Theranostics; 2024; 14(4):1344-1360. PubMed ID: 38389832 [No Abstract] [Full Text] [Related]
7. In Vivo Characterization of Platinum(II)-Based Linker Technology for the Development of Antibody-Drug Conjugates: Taking Advantage of Dual Labeling with Muns JA; Montserrat V; Houthoff HJ; Codée-van der Schilden K; Zwaagstra O; Sijbrandi NJ; Merkul E; van Dongen GAMS J Nucl Med; 2018 Jul; 59(7):1146-1151. PubMed ID: 29496986 [TBL] [Abstract][Full Text] [Related]
8. PET Imaging of HER2-Positive Tumors with Cu-64-Labeled Affibody Molecules. Qi S; Hoppmann S; Xu Y; Cheng Z Mol Imaging Biol; 2019 Oct; 21(5):907-916. PubMed ID: 30617730 [TBL] [Abstract][Full Text] [Related]
9. Alpha radioimmunotherapy using Cheal SM; McDevitt MR; Santich BH; Patel M; Yang G; Fung EK; Veach DR; Bell M; Ahad A; Vargas DB; Punzalan B; Pillarsetty NVK; Xu H; Guo HF; Monette S; Michel AO; Piersigilli A; Scheinberg DA; Ouerfelli O; Cheung NV; Larson SM Theranostics; 2020; 10(25):11359-11375. PubMed ID: 33052220 [TBL] [Abstract][Full Text] [Related]
10. Comparison of bifunctional chelates for (64)Cu antibody imaging. Ferreira CL; Yapp DT; Crisp S; Sutherland BW; Ng SS; Gleave M; Bensimon C; Jurek P; Kiefer GE Eur J Nucl Med Mol Imaging; 2010 Nov; 37(11):2117-26. PubMed ID: 20552190 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of an Anti-HER2 Nanobody Labeled with Pruszynski M; D'Huyvetter M; Bruchertseifer F; Morgenstern A; Lahoutte T Mol Pharm; 2018 Apr; 15(4):1457-1466. PubMed ID: 29502411 [TBL] [Abstract][Full Text] [Related]
16. Exploring the PET in vivo generator Bauer D; De Gregorio R; Pratt EC; Bell A; Michel A; Lewis JS bioRxiv; 2024 Apr; ():. PubMed ID: 38712285 [TBL] [Abstract][Full Text] [Related]
17. Examination of the PET in vivo generator Bauer D; De Gregorio R; Pratt EC; Bell A; Michel A; Lewis JS Eur J Nucl Med Mol Imaging; 2024 Nov; 51(13):4015-4025. PubMed ID: 38940841 [TBL] [Abstract][Full Text] [Related]
18. Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for Vugts DJ; Klaver C; Sewing C; Poot AJ; Adamzek K; Huegli S; Mari C; Visser GWM; Valverde IE; Gasser G; Mindt TL; van Dongen GAMS Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):286-295. PubMed ID: 27573793 [TBL] [Abstract][Full Text] [Related]